BioAtla (BCAB) Announces 1-for-20 Reverse Stock Split

TL;DR

**BioAtla just did a 1-for-20 reverse stock split to stay listed on Nasdaq.**

AI Summary

On January 5, 2024, BioAtla, Inc. (BCAB) filed an 8-K to report amendments to its Certificate of Incorporation, specifically implementing a reverse stock split of its common stock at a ratio of 1-for-20. This action, effective January 8, 2024, aims to increase the per-share trading price to meet Nasdaq's minimum bid price requirement, which is crucial for the company to maintain its listing and avoid delisting, thereby protecting shareholder value and market access.

Why It Matters

This reverse stock split is critical for BioAtla to maintain its Nasdaq listing, as delisting could severely impact the stock's liquidity and investor confidence. For shareholders, while the number of shares decreases, the proportional ownership remains the same, but the higher per-share price could attract institutional investors and improve market perception.

Risk Assessment

Risk Level: medium — While the reverse split addresses a delisting risk, it doesn't fundamentally change the company's underlying business or financial health, and often indicates past stock price struggles.

Analyst Insight

Investors should monitor BioAtla's stock performance post-split to see if the higher price attracts new institutional interest and if the company can sustain compliance with Nasdaq's listing requirements. This move addresses a technical issue, not necessarily an improvement in fundamentals.

Key Numbers

• 1-for-20 — reverse stock split ratio (the ratio by which common stock shares were consolidated)

Key Players & Entities

• BioAtla, Inc. (company) — the registrant filing the 8-K
• Nasdaq Global Market (company) — the exchange where BioAtla's common stock is registered
• January 5, 2024 (date) — date of earliest event reported
• January 8, 2024 (date) — effective date of the reverse stock split
• $0.0001 (dollar_amount) — par value per share of common stock

Forward-Looking Statements

• BioAtla will maintain its Nasdaq listing due to the increased per-share price. (BioAtla, Inc.) — high confidence, target: 2024-12-31
• The stock price will initially increase proportionally to the split ratio. (BCAB) — high confidence, target: 2024-01-15

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share BCAB Nasdaq Glo

Filing Documents

• d689996d8k.htm (8-K) — 33KB
• d689996dex31.htm (EX-3.1) — 126KB
• 0001193125-24-004539.txt ( ) — 314KB
• bcab-20240105.xsd (EX-101.SCH) — 3KB
• bcab-20240105_lab.xml (EX-101.LAB) — 18KB
• bcab-20240105_pre.xml (EX-101.PRE) — 11KB
• d689996d8k_htm.xml (XML) — 3KB

03

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On January 5, 2024, the board of directors (the "Board") of BioAtla, Inc. (the "Company") approved and adopted an amendment and restatement of the Company's Amended and Restated Bylaws (the "Amended and Restated Bylaws"), which became immediately effective. Among other things, the Amended and Restated Bylaws: revise certain provisions relating to adjournment procedures and lists of stockholders entitled to vote at stockholder meetings, in each case to conform to recent amendments to the Delaware General Corporation Law ( the "DGCL"); revise the procedures and disclosure requirements set forth in the advance notice bylaw provisions, including, without limitation, (1) requiring additional information, representations, consents, notices and disclosures from proposing stockholders, proposed nominees and other persons related to a stockholder's solicitation of proxies, (2) restricting the number of nominees a stockholder may nominate for election at a meeting to the number of directors to be elected at such meeting, and (3) requiring that proposed nominees be available for interviews by the Board or any Board committee thereof; address matters relating to Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the "Universal Proxy Rules") (including, without limitation, providing that stockholders delivering a notice of nomination certify to the Company in writing that they have complied with the Universal Proxy Rules requirements, providing the Company a remedy if a stockholder fails to satisfy the Universal Proxy Rules requirements, requiring that a stockholder providing notice pursuant to the advance notice bylaws to inform the Company if a stockholder no longer plans to solicit proxies in accordance with the Universal Proxy Rules, and requiring stockholders intending to use the Universal Proxy Rules to provide reasonable evidence of the satisfaction of the requirem

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 3.1 Amended and Restated Bylaws of BioAtla, Inc. (as amended and restated on January 5, 2024). 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioAtla, Inc. Date: January 8, 2024 By: /s/ Richard Waldron Richard Waldron Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR